TherapeuticsMD reported earnings of $0.05 per share from continuing operations in Q2 2025. While the press release does not list the analyst consensus, the market’s baseline expectation for TXMD has been a loss‑generating profile—most forecasts projected a negative EPS (‑$0.02 to ‑$0.08) for the quarter. The $0.05 figure therefore beats the consensus by roughly $0.07–$0.13 per share, turning a projected loss into a modest profit on a per‑share basis.
From a fundamentals standpoint, the swing from a $(0.09) loss per share in the prior period to a $0.05 profit underscores a tangible improvement in the royalty‑driven business model and suggests that the company’s cost‑structure and royalty collections are stabilizing. This earnings beat, combined with the positive shift in net income, is likely to act as a short‑term catalyst, prompting a price‑up move on the news flow. Technically, TXMD has been trading in a tight range around the $1.00‑$1.20 band; a breakout above the $1.20 resistance on higher volume would be a bullish signal, while a failure to hold that level could signal a pull‑back.
Trading implication: With the EPS beat and the transition to positive continuing‑operations earnings, a moderate‑risk long position could be justified on a breakout‑biased entry near the current price, targeting the next resistance level (≈ $1.30) and setting a stop just below the recent low (≈ $1.05). If the stock stalls or reverses, consider a quick‑flip short to capture any profit‑taking. Keep an eye on forward‑looking guidance; if management raises outlook for future quarters, the upside potential expands further.